Sudeep Pharma Limited IPO: Issue Price, Listing Gain and Share Price Now
Sudeep Pharma Limited listed on 28-Nov-2025 at ₹773.7 against an issue price of ₹593 , a listing gain of +30.47%. It last traded at ₹1,112.6. This page is the record of that issue and what has happened to it since — reported figures only.
Sudeep Pharma Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹593 |
| Listing price (listing-day close) | ₹773.7 |
| Listing gain | +30.47% |
| Price now | ₹1,112.6 |
| Change from issue price | +87.62% |
| Change from listing-day close | +43.80% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Sudeep Pharma Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹593 |
| Issue size | ₹895 Cr |
| Fresh issue | ₹95 Cr |
| Offer for sale | ₹800 Cr |
| Issue opened | 21-Nov-2025 |
| Issue closed | 25-Nov-2025 |
| Listed on | 28-Nov-2025 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | ICICI Securities (left lead) |
How the Sudeep Pharma Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 213.08x |
| NII | 116.72x |
| Retail | 15.65x |
| Total | 93.71x |
Sudeep Pharma Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹12,517 Cr |
| Trailing P/E | 68.50x |
| Return on capital employed | 28.2% |
| Return on equity | 25.2% |
| 52-week high | ₹1,189 |
| 52-week low | ₹524 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Sudeep Pharma Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.